OREANDA-NEWS. Daiichi Sankyo Co., Ltd. and Sanofi Pateur KK announced that Kitasato Daiichi Sankyo K.K., a member of the Daiichi Sankyo Group, has applied for approval of “tetravalent combination vaccine (DPT-IPV)” in Japan for the prevention of Diphtheria, Pertussis (whooping cough), Tetanus, and acute Poliomyelitis (polio).

The DPT-IPV vaccine, which is supplied in pre-filled syringes, combines DPT vaccine from Kitasato Daiichi Sankyo and the enhanced inactivated Salk Poliomyelitis vaccine (eIPV), from Sanofi Pasteur. 

The Daiichi Sankyo Group and Sanofi Pasteur contribute to the protection and improvement of people’s health and hygiene and the enhancement and dissemination of preventive medicine in Japan by supplying vaccines that meet unmet medical needs.